Table 1.
Demographic data of patients and controls*
| Cohort | Whole blood | Circulating lymphocyte subsets | Circulating B cell subsets | Bulk synovial tissue | |
|---|---|---|---|---|---|
| eRA (n = 56) | eRA (n = 8) | eRA (n = 4) | ePsA (n = 4) | eRA (n = 22) | |
| Age, median (range), yr | 58 (30–87) | 56 (49–64) | 62 (63–78) | 62 (60–80) | 63 (41–78) |
| Sex ratio, M:F | 1:1.8 | 3:1 | 1:1 | 1:1 | 1:1 |
| Seropositive (either anti‐CCP or RF), n (%) | 43 (77) | 8 (100) | 4 (100) | 0 | 14 (64) |
| CRP, median (range) | 8 (4–114) | 7 (4–56) | 9 (4–127) | 7 (4–167) | 22 (4–62) |
| DAS‐28‐ESR, median (range) | 4.3 (1.3–7.6) | 3.71 (1.63–6.18) | 4.47 (1.33–8.53) | n/a | 4.74 (2.47–7) |
*
Anti‐CCP, anti–citrullinated peptide; CRP, C‐reactive protein; DAS‐28‐ESR, Disease Activity Score‐28 using the erythrocyte sedimentation rate; ePsA, early psoriatic arthritis; eRA, early rheumatoid arthritis; F, female; M, male; n/a, not applicable; RF, rheumatoid factor.